Experts concluded the drug, which slows the progression of the disease for some people, did not have therapeutic value

A scientist looks at scans at the Memory Centre at the Department of Readaptation and Geriatrics of the University Hospital in Geneva, Switzerland. The Health Canada-approved drug, lecanemab, slows progression of Alzheimer’s disease by 27 per cent on average, according to the main clinical trial that led to regulatory approval.

Quebec will not publicly fund the first Health Canada-approved treatment for the underlying cause of Alzheimer’s disease after an expert committee concluded its benefits are too modest to improve patients’ lives.

The negative recommendation from Quebec’s National Institute for Excellence in Health and Social Services, known by the French acronym INESSS, marks the first time a government advisory body in Canada has evaluated whether the medication, lecanemab, should be paid for out of the public purse.

From The Globe and Mail via this RSS feed